300003 乐普医疗
交易中 10-20 13:45:36
资讯
新帖
简况
乐普医疗（300003）10月13日主力资金净卖出1647.04万元
证券之星 · 10-14
乐普医疗（300003）10月13日主力资金净卖出1647.04万元
乐普医疗最新公告：子公司MWN117注射液获美国FDA临床试验批准
证券之星 · 10-08
乐普医疗最新公告：子公司MWN117注射液获美国FDA临床试验批准
乐普医疗（300003）9月30日主力资金净买入795.67万元
证券之星 · 10-08
乐普医疗（300003）9月30日主力资金净买入795.67万元
乐普医疗最新公告：子公司MWN110注射液获美国FDA临床试验批准
证券之星 · 09-28
乐普医疗最新公告：子公司MWN110注射液获美国FDA临床试验批准
公司问答丨乐普医疗：三文鱼针目前正处于国家药品监督管理局的审评审批阶段 尚未取得正式注册批件
格隆汇 · 09-14
公司问答丨乐普医疗：三文鱼针目前正处于国家药品监督管理局的审评审批阶段 尚未取得正式注册批件
公司问答丨乐普医疗：候选药物MWN109注射液超重、肥胖适应症已完成II期临床试验 预计将在2026年内启动入组工作
格隆汇 · 09-14
公司问答丨乐普医疗：候选药物MWN109注射液超重、肥胖适应症已完成II期临床试验 预计将在2026年内启动入组工作
公司问答丨乐普医疗：赛乐提产品目前已经开始产生销售 正积极推进该产品的商业化工作
格隆汇 · 09-14
公司问答丨乐普医疗：赛乐提产品目前已经开始产生销售 正积极推进该产品的商业化工作
乐普医疗旗下APP被通报 违法违规收集使用个人信息
中金财经 · 09-07
乐普医疗旗下APP被通报 违法违规收集使用个人信息
乐普医疗上半年净利暴跌超30％，核心产品遭欧洲四国禁售
微博财经-财道工作室 · 08-31
乐普医疗上半年净利暴跌超30％，核心产品遭欧洲四国禁售
股市必读：乐普医疗（300003）8月25日披露最新机构调研信息
证券之星 · 08-26
股市必读：乐普医疗（300003）8月25日披露最新机构调研信息
乐普医疗（300003）2026年中报简析：净利润同比下降27.71%，公司应收账款体量较大
证券之星 · 08-23
乐普医疗（300003）2026年中报简析：净利润同比下降27.71%，公司应收账款体量较大
乐普医疗(300003)6月30日股东户数10.4万户，较上期减少4.41%
证券之星 · 08-22
乐普医疗(300003)6月30日股东户数10.4万户，较上期减少4.41%
图解乐普医疗中报：第二季度单季净利润同比下降19.12%
证券之星 · 08-22
图解乐普医疗中报：第二季度单季净利润同比下降19.12%
乐普医疗（300003）披露2026年半年度报告，8月21日股价下跌4.92%
证券之星 · 08-21
乐普医疗（300003）披露2026年半年度报告，8月21日股价下跌4.92%
乐普医疗最新公告：拟申请3.15亿元并购贷款
证券之星 · 08-21
乐普医疗最新公告：拟申请3.15亿元并购贷款
乐普医疗最新公告：拟10.88亿元向心泰医疗转让上海民为生物54.2384%股权
证券之星 · 08-21
乐普医疗最新公告：拟10.88亿元向心泰医疗转让上海民为生物54.2384%股权
乐普医疗最新公告：子公司MWN117注射液获临床试验批准
证券之星 · 08-17
乐普医疗最新公告：子公司MWN117注射液获临床试验批准
乐普医疗（300003）披露持股5%以上股东拟发行科技创新可交换债获深交所无异议函，8月13日股价上涨1.23%
证券之星 · 08-13
乐普医疗（300003）披露持股5%以上股东拟发行科技创新可交换债获深交所无异议函，8月13日股价上涨1.23%
乐普医疗最新公告：子公司MWN110注射液获临床试验批准
证券之星 · 07-15
乐普医疗最新公告：子公司MWN110注射液获临床试验批准
乐普医疗（300003）披露控股股东部分股权质押及解除质押公告，7月13日股价下跌1.71%
证券之星 · 07-13
乐普医疗（300003）披露控股股东部分股权质押及解除质押公告，7月13日股价下跌1.71%
加载更多
公司概况
公司名称：
乐普(北京)医疗器械股份有限公司
所属行业：
专用设备制造业
上市日期：
2009-10-30
主营业务：
乐普(北京)医疗器械股份有限公司的主营业务是医疗器械及其配件的技术开发、生产，销售。公司的主要产品是医疗器械、药品、医疗服务、健康管理。公司作为国内最早研发心血管植介入器械的企业之一，拥有国家科技部授予的“国家心脏病植介入诊疗器械及装备工程技术研究中心”称号。
发行价格：
29.00
{"stockData":{"symbol":"300003","market":"SZ","secType":"STK","nameCN":"乐普医疗","latestPrice":11.51,"timestamp":1792475136000,"preClose":11.34,"halted":0,"volume":10503111,"delay":0,"changeRate":0.015,"floatShares":1579000000,"shares":1843000000,"eps":0.4181,"marketStatus":"交易中","change":0.17,"latestTime":"10-20 13:45:36","open":11.32,"high":11.54,"low":11.28,"amount":120000000,"amplitude":0.0229,"askPrice":11.52,"askSize":223,"bidPrice":11.51,"bidSize":67,"shortable":0,"etf":0,"ttmEps":0.4181,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792479600000},"marketStatusCode":2,"adr":0,"adjPreClose":11.34,"symbolType":"stock","openAndCloseTimeList":[[1792459800000,1792467000000],[1792472400000,1792479600000]],"highLimit":12.47,"lowLimit":10.21,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1843424716,"isCdr":false,"pbRate":1.27,"roa":"--","peRate":27.529299,"roe":"3.05%","epsLYR":0.5219,"committee":-0.693768,"marketValue":21218000000,"turnoverRate":0.0067,"status":0,"floatMarketCap":18173000000},"requestUrl":"/m/hq/s/300003","defaultTab":"news","newsList":[{"id":"2675399660","title":"乐普医疗（300003）10月13日主力资金净卖出1647.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675399660","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675399660?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:17","pubTimestamp":1791940675,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，乐普医疗报收于11.5元，下跌1.88%，换手率1.0%，成交量15.78万手，成交额1.81亿元。近5日资金流向一览见下表：乐普医疗融资融券信息显示，融资方面，当日融资买入1726.34万元，融资偿还1225.14万元，融资净买入501.2万元。乐普医疗主营业务：提供心血管疾病领域全生命周期的整体解决方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400008472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0251","BK0028","BK0201","BK0042","BK0188","BK0196","BK0113","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673007640","title":"乐普医疗最新公告：子公司MWN117注射液获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2673007640","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673007640?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:41","pubTimestamp":1791456064,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司控股子公司上海民为生物技术有限公司获得美国FDA关于同意MWN117注射液开展临床试验的通知书。该药品为靶向抑制INHBE的siRNA药物，适应症为超重或肥胖，目前已获CDE临床试验批准。非临床研究显示，该药物单用或与GLP-1受体激动剂联用均能有效降低体重和体脂，同时减少肌肉流失，药效持续至12周。目前国内外尚无同类药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800027444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0201","BK0028","BK0251","BK0113","BK0196","BK0114","300003","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673041817","title":"乐普医疗（300003）9月30日主力资金净买入795.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673041817","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673041817?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:09","pubTimestamp":1791421779,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，乐普医疗报收于11.66元，上涨2.37%，换手率1.11%，成交量17.58万手，成交额2.04亿元。近5日资金流向一览见下表：乐普医疗融资融券信息显示，融资方面，当日融资买入1883.07万元，融资偿还4111.8万元，融资净偿还2228.73万元。乐普医疗主营业务：提供心血管疾病领域全生命周期的整体解决方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800003049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0188","BK0042","BK0196","BK0201","BK0251","BK0028","300003","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670239542","title":"乐普医疗最新公告：子公司MWN110注射液获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239542","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670239542?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:40","pubTimestamp":1790592009,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司控股子公司上海民为生物获得美国FDA关于同意MWN110注射液开展临床试验的通知书。该药品为靶向ActRIIA/B的单克隆抗体，申请适应症为超重或肥胖，拥有全球知识产权，已于2026年7月获得CDE临床试验批准。非临床研究显示，该药品单用能显著降低体脂率、体重并增加肌肉量，与司美格鲁肽联用可抑制肌肉流失。目前国内外尚无同类药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800026251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0113","BK0114","BK0042","BK0251","BK0188","BK0028","BK0196","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654867","title":"公司问答丨乐普医疗：三文鱼针目前正处于国家药品监督管理局的审评审批阶段 尚未取得正式注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654867","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654867?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:16","pubTimestamp":1789377364,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0251","300003","BK0188","BK0201","BK0113","BK0042","BK0196","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667013651","title":"公司问答丨乐普医疗：候选药物MWN109注射液超重、肥胖适应症已完成II期临床试验 预计将在2026年内启动入组工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667013651","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667013651?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:14","pubTimestamp":1789377296,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0201","BK0042","300003","BK0196","BK0113","BK0251","BK0114","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659950","title":"公司问答丨乐普医疗：赛乐提产品目前已经开始产生销售 正积极推进该产品的商业化工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659950","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659950?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:31","pubTimestamp":1789374675,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0113","BK0188","300003","BK0201","BK0196","BK0042","BK0028","BK0114","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392350","title":"乐普医疗旗下APP被通报 违法违规收集使用个人信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392350","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665392350?lang=zh_cn&edition=full","pubTime":"2026-09-07 14:48","pubTimestamp":1788763687,"startTime":"0","endTime":"0","summary":"中国经济网北京9月7日讯 国家网络安全通报中心微信公众号9月1日发布消息“公安部计算机信息系统安全产品质量监督检验中心检测发现42款违法违规收集使用个人信息的移动应用”。经公安部计算机信息系统安全产品质量监督检验中心检测，42款移动应用存在一项或者多项违法违规收集使用个人信息情况。 其中，《乐普健康》存在以下问题：未经用户同意收集使用个人信息。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/07/20260907506905.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/07/20260907506905.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260907/32361925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0114","BK0188","BK0113","BK0201","BK0251","BK0196","BK0042","BK0028","300003"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070076","title":"乐普医疗上半年净利暴跌超30％，核心产品遭欧洲四国禁售","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070076","media":"微博财经-财道工作室","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663070076?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:05","pubTimestamp":1788174300,"startTime":"0","endTime":"0","summary":"国内遭遇集采的同时，乐普医疗的封堵器产品在海外还面临了“四国”封锁。乐普“产品未在五国销售、不构成实质侵权”的抗辩未被采纳。更具戏剧性的是，乐普在上诉阶段未现场出庭，仅提交书面抗辩材料。药品毛利率为56.59%，同比下滑6.16个百分点。财务费用激增177%此外，乐普医疗财报中最刺眼的数字来自财务费用，上半年高达1.72亿元，同比激增177%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-08-31/doc-iniqfkkr8808016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0114","BK0113","BK0028","BK0201","300003","BK0042","BK0196","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662544347","title":"股市必读：乐普医疗（300003）8月25日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2662544347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662544347?lang=zh_cn&edition=full","pubTime":"2026-08-26 04:08","pubTimestamp":1787688495,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，乐普医疗报收于11.96元，上涨2.13%，换手率1.4%，成交量22.07万手，成交额2.62亿元。民为生物整合安排：民为生物为乐普2023年孵化的创新药企业，上半年近50%研发费用投向创新药；整合至心泰医疗主要基于四方面考量：提升创新药独立估值、适配差异化管理模式与人才机制、利用港股平台增强融资能力、强化对核心研发人员的激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600007716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300003","BK0196","BK0042","BK0201","BK0114","BK0113","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212528","title":"乐普医疗（300003）2026年中报简析：净利润同比下降27.71%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661212528?lang=zh_cn&edition=full","pubTime":"2026-08-23 06:13","pubTimestamp":1787436795,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期乐普医疗发布2026年中报。截至本报告期末，公司营业总收入32.14亿元，同比下降4.61%，归母净利润4.99亿元，同比下降27.71%。本报告期乐普医疗公司应收账款体量较大，当期应收账款占最新年报归母净利润比达243.46%。持有乐普医疗最多的基金为医疗器械ETF永赢，目前规模为38.29亿元，最新净值0.4447，较上一交易日下跌2.22%，近一年下跌20.29%。本文数据来源于乐普医疗2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300001921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661164742","title":"乐普医疗(300003)6月30日股东户数10.4万户，较上期减少4.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661164742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661164742?lang=zh_cn&edition=full","pubTime":"2026-08-22 17:08","pubTimestamp":1787389734,"startTime":"0","endTime":"0","summary":"证券之星消息，近日乐普医疗披露，截至2026年6月30日公司股东户数为10.4万户，较3月31日减少4800.0户，减幅为4.41%。在医疗器械行业个股中，乐普医疗股东户数高于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.15万户。从股价来看，2026年3月31日至2026年6月30日，乐普医疗区间跌幅为25.86%，在此期间股东户数减少4800.0户，减幅为4.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200015026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0114","BK0251","BK0028","BK0042","BK0188","BK0201","BK0113","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661947022","title":"图解乐普医疗中报：第二季度单季净利润同比下降19.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661947022","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661947022?lang=zh_cn&edition=full","pubTime":"2026-08-22 01:50","pubTimestamp":1787334650,"startTime":"0","endTime":"0","summary":"证券之星消息，乐普医疗2026年中报显示，上半年度公司主营收入32.14亿元，同比下降4.61%；归母净利润4.99亿元，同比下降27.71%；扣非净利润4.81亿元，同比下降27.4%；其中2026年第二季度，公司单季度主营收入15.42亿元，同比下降5.57%；单季度归母净利润2.53亿元，同比下降19.12%；单季度扣非净利润2.39亿元，同比下降26.31%；负债率31.75%，投资收益1334.04万元，财务费用1.72亿元，毛利率60.86%。财报数据概要请见下图:本文数据来源于乐普医疗2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200002045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661295048","title":"乐普医疗（300003）披露2026年半年度报告，8月21日股价下跌4.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661295048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661295048?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:06","pubTimestamp":1787321217,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，乐普医疗报收于12.17元，较前一交易日下跌4.92%，最新总市值为224.34亿元。近日，乐普医疗披露2026年半年度报告。报告显示，本报告期营业收入为3,214,194,092.31元，较上年同期下降4.61%；归属于上市公司股东的净利润为499,475,609.79元，同比下降27.71%；扣除非经常性损益后的净利润为480,755,800.14元，同比下降27.40%。本报告期末总资产为26,172,543,209.33元，较上年度末增长0.13%；归属于上市公司股东的净资产为16,397,670,089.36元，较上年度末增长1.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100045078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","300003","BK0188","BK0201","BK0113","BK0042","BK0196","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262184","title":"乐普医疗最新公告：拟申请3.15亿元并购贷款","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661262184?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:51","pubTimestamp":1787309487,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司召开董事会审议通过议案，拟向兴业银行申请不超过3.15亿元并购贷款，用于支付或置换乐普药业收购百奥泰生物制药作为药品上市许可持有人的贝塔宁涉及的药品上市许可证、知识产权、生产技术及商业化权益等全部无形资产转让款。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100035379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300003","BK0201","BK0196","BK0042","BK0028","BK0114","BK0188","BK0251","BK0113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661926292","title":"乐普医疗最新公告：拟10.88亿元向心泰医疗转让上海民为生物54.2384%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2661926292","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661926292?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:50","pubTimestamp":1787309446,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司将持有的上海民为生物54.2384%股权转让给控股子公司心泰医疗，转让价款10.88亿元。本次交易属于公司内部股权转让，不涉及合并报表范围变化。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100035378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02291","BK0251","BK0114","300003","BK0028","BK0042","BK0201","BK0188","BK1100","BK0113","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484463","title":"乐普医疗最新公告：子公司MWN117注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484463","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660484463?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:09","pubTimestamp":1786964968,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司控股子公司上海民为生物收到国家药监局核准签发的《药物临床试验批准通知书》，MWN117注射液临床试验申请获批准，适应症为超重或肥胖。该药物为自主研发的靶向抑制INHBE的siRNA药物，拥有全球知识产权，目前国内外尚无同类药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700028169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0188","BK0113","BK0201","BK0251","BK0196","BK0042","BK0028","300003"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168461","title":"乐普医疗（300003）披露持股5%以上股东拟发行科技创新可交换债获深交所无异议函，8月13日股价上涨1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168461?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:14","pubTimestamp":1786630460,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，乐普医疗报收于13.16元，较前一交易日上涨1.23%，最新总市值为242.59亿元。该股当日开盘12.92元，最高13.38元，最低12.77元，成交额达6.96亿元，换手率为3.35%。乐普医疗当日发布《关于持股5%以上股东拟非公开发行科技创新可交换公司债券获得深圳证券交易所无异议函的提示性公告》。截至公告日，七二五所持有公司244,063,788股，占总股本13.24%。公司将按规定履行后续信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0188","BK0113","BK0201","BK0251","BK0196","BK0042","BK0028","300003"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651454029","title":"乐普医疗最新公告：子公司MWN110注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651454029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651454029?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:31","pubTimestamp":1784111505,"startTime":"0","endTime":"0","summary":"乐普医疗(300003.SZ)公告称，公司控股子公司上海民为生物技术有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其申报的MWN110注射液临床试验申请获批，适应症为成人体重控制。该药物为靶向ActRIIA/B的单克隆抗体，非临床研究显示其可显著降低体脂率、体重并增加肌肉量，与司美格鲁肽联用可抑制肌肉流失，且安全性良好。目前国内外尚无同类药物上市，但后续临床试验存在不确定性风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500037608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0251","300003","BK0113","BK0042","BK0188","BK0201","BK0196","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651819078","title":"乐普医疗（300003）披露控股股东部分股权质押及解除质押公告，7月13日股价下跌1.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651819078","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651819078?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:46","pubTimestamp":1783936007,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，乐普医疗报收于12.09元，较前一交易日下跌1.71%，最新总市值为222.87亿元。乐普医疗近日披露《关于控股股东部分股权质押及解除质押的公告》。本次解除质押32,000,000股，占其所持股份比例7.02%，占公司总股本1.74%；同时新质押40,750,000股，占其所持股份比例8.94%，占公司总股本2.21%，质押用途为偿还债务，质权人均为中国银河证券股份有限公司。截至公告日，蒲忠杰及其一致行动人累计质押股份190,419,996股，占其持股总数的41.79%，占公司总股本10.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300026589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0201","300003","BK0042","BK0251","BK0113","BK0028","BK0114","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792475140012,"stockEarnings":[{"period":"1week","weight":-0.0324},{"period":"1month","weight":-0.0096},{"period":"3month","weight":-0.123},{"period":"6month","weight":-0.3003},{"period":"1year","weight":-0.3347},{"period":"ytd","weight":-0.2729}],"compareEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":-0.0463},{"period":"3month","weight":-0.0345},{"period":"6month","weight":-0.0914},{"period":"1year","weight":-0.0283},{"period":"ytd","weight":-0.0599}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"乐普(北京)医疗器械股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"103951人(较上一季度减少4.41%)","perCapita":"15189股","listingDate":"2009-10-30","address":"北京市昌平区超前路37号","registeredCapital":"184342万元","survey":" 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械及其配件的技术开发、生产，销售。公司的主要产品是医疗器械、药品、医疗服务、健康管理。公司作为国内最早研发心血管植介入器械的企业之一，拥有国家科技部授予的“国家心脏病植介入诊疗器械及装备工程技术研究中心”称号。","listedPrice":29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普医疗,300003,乐普医疗股票,乐普医疗股票老虎,乐普医疗股票老虎国际,乐普医疗行情,乐普医疗股票行情,乐普医疗股价,乐普医疗股市,乐普医疗股票价格,乐普医疗股票交易,乐普医疗股票购买,乐普医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普医疗(300003)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普医疗(300003)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}